A virus that almost everyone carries is finally meeting a tailored molecular rival. Infecting around 95% of humans, Epstein‑Barr virus has long slipped past immune surveillance, yet new work shows an engineered antibody can lock onto its entry machinery and stop the pathogen from invading B cells in laboratory models.
This looks less like incremental progress and more like a reset of the field. By targeting the viral glycoprotein complexes that mediate membrane fusion, the antibody blocks attachment to the CD21 receptor and prevents fusion with the host cell membrane, a classic one‑two hit in virology terms. In neutralization assays it shut down infection at far lower concentrations than earlier candidates, and structural biology data indicate a highly conserved epitope, hinting that viral escape mutations may carry a steep fitness cost.
The bigger claim is that this single molecule could reframe how clinicians think about lifelong latent infection. Because Epstein‑Barr virus is linked to certain lymphomas and autoimmune disease, an antibody that interferes with both primary infection and reactivation could support prophylactic use in high‑risk groups and serve as a scaffold for future vaccine antigens, turning a nearly universal passenger into a more manageable risk.
